Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
NYSE MKT:PHGE
Holding PHGE?
Track your performance easily
PHGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.94 - $8.56
Previous Close$1.02
Volume70.96K
Average Volume (3M)52.77K
Market Cap
$18.25M
Enterprise Value-$3.46M
Total Cash (Recent Filing)$31.61M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Nov 13, 2024EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.97
Shares Outstanding17,895,845
10 Day Avg. Volume52,639
30 Day Avg. Volume52,770
Standard Deviation0.27
R-Squared0.06
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)-3.64
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.15
Forecast
1Y Price Target
$20.00Price Target Upside1849.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
BiomX News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company announced positive safety and efficacy results from its Phase 1b/2a trial evaluating BX004 in chronic pulmonary infections caused by P. aeruginosa in CF patients.
Drug DevelopmentThe recent merger with Adaptive Phage Therapy expanded BiomX’s pipeline with the addition of BX211.
Financial StabilityManagement believes available cash should provide runway for ongoing operations through 4Q25.
Bears Say
EarningsBiomX announced financial results, posting EPS of ($0.28) compared with analyst estimate of ($0.07); the difference came from warrant accounting.
FundingDespite completing the 2024 March PIPE, management believes the company will likely need additional funding in the future to support its operating expenses and capital requirements.
Stock PriceThe dilution led to a reduced price target of $2 from $4.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PHGE FAQ
What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $0.94 and its highest was $8.56 in the past 12 months.
What is BiomX’s market cap?
Currently, no data Available
When is BiomX’s upcoming earnings report date?
BiomX’s upcoming earnings report date is Nov 13, 2024 which is in 54 days.
How were BiomX’s earnings last quarter?
BiomX released its earnings results on Aug 15, 2024. The company reported -$0.7 earnings per share for the quarter, beating the consensus estimate of -$0.867 by $0.167.
Is BiomX overvalued?
According to Wall Street analysts BiomX’s price is currently Undervalued.
Does BiomX pay dividends?
BiomX does not currently pay dividends.
What is BiomX’s EPS estimate?
BiomX’s EPS estimate is -$0.5.
How many shares outstanding does BiomX have?
BiomX has 17,895,845 shares outstanding.
What happened to BiomX’s price movement after its last earnings report?
BiomX reported an EPS of -$0.7 in its last earnings report, beating expectations of -$0.867. Following the earnings report the stock price went down -11.413%.
Which hedge fund is a major shareholder of BiomX?
Among the largest hedge funds holding BiomX’s share is Deerfield Management Company, LP. It holds BiomX’s shares valued at 2M.
---
BiomX Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (1849.32% Upside)
$20.00 (1849.32% Upside)
Hedge Fund Trend
Decreased
By 182.0 Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.43%
12-Months-Change
Fundamentals
Return on Equity
-137.53%
Trailing 12-Months
Asset Growth
66.34%
Trailing 12-Months
Company Description
BiomX
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
---
PHGE Earnings Call
Q2 2024
0:00 / 0:00
---
PHGE Stock 12 Month Forecast
Average Price Target
$20.00
▲(1849.32% Upside)
Technical Analysis
Best Analysts Covering PHGE
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-50.37%
reiterated a buy rating last month
Copying Michael Higgins's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -50.37% per trade.
---